Corporate Profile

La Jolla Pharmaceutical Company is a publicly traded biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases.

Featured Documents

12/22/17GIAPREZA™ (angiotensin II) Update

Share Price

Stock chart for: LJPC.OQ.  Currently trading at $30.23 with a 52 week high of $41.24 and a 52 week low of $22.68.
Price$30.23
Change (%) Stock is Down 0.02 (0.07%)
Volume60,885
Data as of 04/24/18 1:32 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.


Upcoming Events




There are currently no events scheduled.

Recent News


La Jolla Pharmaceutical Company Announces Launch of GIAPREZA™ (angiotensin II) in the United States

03/22/18

SAN DIEGO, March 22, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC) today announced that GIAPREZA™ (angiotensin II), injection for intravenous infusion, is now commercially available. In December 2017, GIAPREZA was approved

Read More

La Jolla Pharmaceutical Company Announces Pricing of Public Offering of Common Stock

03/15/18

SAN DIEGO, March 15, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC) (La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening disea

Read More

La Jolla Pharmaceutical Company Announces $100 Million Public Offering of Common Stock

03/14/18

SAN DIEGO, March 14, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC) (La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening disea

Read More



Print Page Print PageE-mail Page E-mail PageRSS Feeds RSS FeedsE-mail Alerts E-mail AlertsIR Contacts IR Contacts